Skip to main
CRIS

Curis (CRIS) Stock Forecast & Price Target

Curis (CRIS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Curis is a biotechnology company that specializes in the development and commercialization of drugs and therapies for solid tumors and a variety of cancers. The company's pipeline products, including Fimepinostat, CA-170, and Erivedge, show promise in treating various types of cancers, with encouraging data and high response rates in recent trials. With a robust portfolio and a strategic focus on expanding its drugs across different cancer subtypes, Curis is well positioned for growth and success in the future.

Bears say

Curis is facing challenges with its pipeline products in the immuno-oncology and precision oncology therapeutic areas due to slower-than-expected enrollment in its registrational trial for PCNSL, potentially delaying full approval and revenue generation. Additionally, the company may struggle with funding a randomized, three-arm study in a rare CNS lymphoma population ahead of its submission, further compounding its financial pressures. Given these challenges and potential delays, Curis's stock outlook remains negative.

Curis (CRIS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Curis (CRIS) Forecast

Analysts have given Curis (CRIS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Curis (CRIS) has a Strong Buy consensus rating as of Aug 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Curis (CRIS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.